Global Monoclonal Antibody Market to Witness Remarkable Growth
As the number of mAbs reaching market has increased, the market for global antibody market surged to US$ 39.6 Billion in 2009, RNCOS acknowledged.

Our report has found that, monoclonal antibody therapy has emerged as a relatively new innovation in cancer treatment. Monoclonal antibodies have specificity for their target molecules and the ability to either activate or suppress the molecular function of the target, thus leading to enhanced immune response. Colorectal cancer had the largest 35% share in monoclonal antibody oncology market in 2009, followed by breast cancer at 32.5% share.
The report "Global Monoclonal Antibody Market Analysis" covers almost all the key aspects of the market and analyzes current market developments in regions, such as the United States, Europe, Japan, China, and India. Moreover, the report provides an analysis on major drugs in monoclonal antibody market and illustrates their sales patterns. Further, it also analyzes the key market alliances and acquisitions in recent times and describes their impact on the sector's profitability.
The report is an outcome of an in-depth research and prudent analysis of the global monoclonal antibody market, with significant emphasis on data reliability and content presentation. The report covers key application areas, where the use of monoclonal antibodies has strengthened during the past few years and analyzes their market potential. Last but not the least, description and recent developments of major industry players seek to enhance knowledge portfolio of our clients.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM279.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm
About RNCOS:
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.
###
Tag Words:
merck
Categories: Biotech
Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707